Study Results Presented In The New England Journal of Medicine Strengthen Hansa Medical’s Belief In The Potential Of IdeS

MALMÖ, Sweden--(BUSINESS WIRE)--Regulatory News:

A recent study published on March 10, 2016 in the New England Journal of Medicine (Orandi et al. 2016;374:940-50) demonstrates a clear survival benefit in patients who received kidney transplants from HLA-incompatible live donors, compared to patients who remained on the waiting list for kidneys from deceased donors, or no transplant at all.

“The study highlights the need for and benefit from desensitization in kidney transplantation. Although IdeS was not subject of this study, it strengthens our belief that IdeS has the potential to play a very important role in kidney transplantation going forward. Our vision for IdeS is to make desensitization possible for highly and moderately HLA-sensitized patients relying on either deceased or living donor donation.” comments Göran Arvidson, CEO of Hansa Medical AB.

Current protocols for desensitization, primarily involving plasmapheresis, immune globulins and rituximab, require meticulous planning and timing and these are not feasible in most cases for deceased donor kidney transplantation.

IdeS with its rapid and powerful pharmacological effect is currently in clinical development. It is administered just prior to transplantation and has the potential to increase the number of sensitized patients receiving kidney transplants. In 2015, 70 percent of donated kidneys in the US were donated from deceased donors.

Informationen i detta pressmeddelande är sådan som Hansa Medical AB (publ) ska offentliggöra i enlighet med lagen om värdepappersmarknaden eller lagen om handel med finansiella instrument. Informationen lämnades för offentliggörande den 11 mars 2016 kl. 08:45.

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.

This information was brought to you by Cision http://news.cision.com